SCHEMBL2234801

SCHEMBL2234801

COC(=O)NN(C(=O)Oc1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.56
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
ATM Q13315 1/20 0.54
KMT2A Q03164 6/20 0.48
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 4/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
GFER P55789 1/20 0.48
NPSR1 Q6W5P4 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
HPGD P15428 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237040 0.91 PTGES (0.48) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2234676 0.90 L3MBTL1 (0.54) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2234591 0.90 L3MBTL1 (0.48) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2236288 0.90 PTGES (0.47) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL27859909 0.89 MTNR1A (0.47) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL28793433 0.86 PTGES (0.44) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2233608 0.85 ALDH1A1 (0.57) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2236717 0.85 ALDH1A1 (0.53) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2232541 0.81 TACR3 (0.43) PTGESTDP1L3MBTL1ATMKMT2A
SCHEMBL2235392 0.81 POLB (0.41) PTGESTDP1L3MBTL1ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102186811-B Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CO LTD 2013-07-24 CN disclosed
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
CN-102186811-A Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CHEMICAL CO 2011-09-14 CN disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR PTGES 1865/4885TDP1 4194/4885L3MBTL1 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.